Combination metronomic oral topotecan and pazopanib

A pharmacokinetic study in patients with gynecological cancer

David C. Turner, Todd Tillmanns, K. Elaine Harstead, Stacy L. Throm, Clinton F. Stewart

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATPbinding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. Patients and Methods: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. Results: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. Conclusion: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.

Original languageEnglish (US)
Pages (from-to)3823-3830
Number of pages8
JournalAnticancer research
Volume33
Issue number9
StatePublished - Sep 1 2013

Fingerprint

Topotecan
Pharmacokinetics
Neoplasms
Drug Interactions
Social Adjustment
Pharmaceutical Preparations
Biological Availability
pazopanib
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Combination metronomic oral topotecan and pazopanib : A pharmacokinetic study in patients with gynecological cancer. / Turner, David C.; Tillmanns, Todd; Harstead, K. Elaine; Throm, Stacy L.; Stewart, Clinton F.

In: Anticancer research, Vol. 33, No. 9, 01.09.2013, p. 3823-3830.

Research output: Contribution to journalArticle

Turner, David C. ; Tillmanns, Todd ; Harstead, K. Elaine ; Throm, Stacy L. ; Stewart, Clinton F. / Combination metronomic oral topotecan and pazopanib : A pharmacokinetic study in patients with gynecological cancer. In: Anticancer research. 2013 ; Vol. 33, No. 9. pp. 3823-3830.
@article{cf521f738df14377a2d7e97457375f30,
title = "Combination metronomic oral topotecan and pazopanib: A pharmacokinetic study in patients with gynecological cancer",
abstract = "Background: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATPbinding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. Patients and Methods: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. Results: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. Conclusion: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.",
author = "Turner, {David C.} and Todd Tillmanns and Harstead, {K. Elaine} and Throm, {Stacy L.} and Stewart, {Clinton F.}",
year = "2013",
month = "9",
day = "1",
language = "English (US)",
volume = "33",
pages = "3823--3830",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Combination metronomic oral topotecan and pazopanib

T2 - A pharmacokinetic study in patients with gynecological cancer

AU - Turner, David C.

AU - Tillmanns, Todd

AU - Harstead, K. Elaine

AU - Throm, Stacy L.

AU - Stewart, Clinton F.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATPbinding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. Patients and Methods: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. Results: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. Conclusion: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.

AB - Background: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATPbinding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. Patients and Methods: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. Results: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. Conclusion: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.

UR - http://www.scopus.com/inward/record.url?scp=84884992334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884992334&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 3823

EP - 3830

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -